US Patent

US11382864 — Solid oral sulfate salt formulations for cleansing a colon and methods of using same

Method of Use · Assigned to Braintree Laboratories Inc · Expires 2037-08-04 · 11y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects solid oral dosage formulations containing sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon.

USPTO Abstract

Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3164 Magnesium Sulfate

Patent Metadata

Patent number
US11382864
Jurisdiction
US
Classification
Method of Use
Expires
2037-08-04
Drug substance claim
No
Drug product claim
No
Assignee
Braintree Laboratories Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.